MUMBAI, 04 November 2025: Demand for revolutionary GLP-1 weight-loss drugs is surging across urban India, yet this explosion in popularity is simultaneously fueling concerns over misuse, black-market sales, and a critical lack of medical supervision.
Physicians like Mumbai-based diabetologist Dr. Rahul Baxi reports a dramatic increase in requests for these powerful injectables originally designed for Type 2 diabetes from young professionals seeking rapid slimming as a lifestyle enhancement rather than a medical necessity. “These are the most powerful weight-loss drugs we’ve ever seen,” states Dr. Anoop Misra, head of the Fortis-C-DOC Centre in Delhi.
The Game Changers: Semaglutide and Tirzepatide
The drugs dominating India’s rapidly growing anti-obesity market which has soared over sixfold to nearly $100 million are semaglutide (marketed as Rybelsus and Wegovy) and tirzepatide (Mounjaro). Both mimic the GLP-1 hormone, suppressing appetite and slowing digestion, forcing users to feel full faster.
However, doctors strongly warn against their casual use:
- Weight Regain: Most users can regain weight within a year of stopping, as the body resists weight loss.
- Muscle Loss: Prolonged use without adequate exercise and protein can lead to sarcopenic obesity (loss of muscle alongside fat gain).
- Side Effects: Risks include common issues like nausea and diarrhea, to rarer conditions like gallstones and pancreatitis.
Misuse and the Looming Generic Flood
The frenzy to shed weight quickly has led to steep ethical challenges. Doctors recount patients being placed on high dosages by gym trainers, dieticians, and beauty clinics with no prescribing authority. Some drugs are sourced via the black market or delivered by online pharmacies after minimal consultation, fueling fears of spurious medicines.
This regulatory challenge is set to escalate dramatically. Investment bank Jefferies predicts a “magic pill moment” when the patent for semaglutide expires in India next March. This expiry could unleash a flood of cheaper generic versions, increasing accessibility and affordability, but also significantly amplifying the risk of widespread misuse.
Despite the risks, the new drugs have helped redefine the conversation around obesity. Experts note that the focus has shifted toward treating obesity as a chronic, relapsing disease, a crucial shift in a country with over 77 million people with Type 2 diabetes and the world’s second-largest number of overweight adults.
